Guidance
← Earnings Calls
01
02
03
04 05 06
Tone
AI
TMO
FY2026 Q1
Raised
Thermo Fisher Scientific Inc earnings call
Buzzberg read
Company raises full-year revenue and EPS guidance.
Thermo Fisher reported a strong Q1 with 6% revenue growth and raised full-year guidance, driven by bioproduction and clinical research strength. Management highlighted AI collaborations with NVIDIA and OpenAI but gave no specific cross-company signals beyond partnership status. The call focused on internal execution, margin expansion, and macro hedging for inflation. Q1 revenue $11.01B (+6% reported, +1% organic); adjusted EPS $5.44 (+6%).
Buzzberg read Company raises full-year revenue and EPS guidance. Thermo Fisher reported a strong Q1 with 6% revenue growth and raised full-year guidance, driven by bioproduction and clinical research strength. Management highlighted AI collaborations with NVIDIA and OpenAI but gave no specific cross-company signals beyond partnership status. The call focused on internal execution, margin expansion, and macro hedging for inflation. Q1 revenue $11.01B (+6% reported, +1% organic); adjusted EPS $5.44 (+6%). Read full analysisCollapse analysis
Thermo Fisher reported a strong Q1 with 6% revenue growth and raised full-year guidance, driven by bioproduction and clinical research strength. Management highlighted AI collaborations with NVIDIA and OpenAI but gave no specific cross-company signals beyond partnership status. The call focused on internal execution, margin expansion, and macro hedging for inflation. Q1 revenue $11.01B (+6% reported, +1% organic); adjusted EPS $5.44 (+6%).
- Full-year revenue guidance raised to $47.3-$48.1B, EPS to $24.64-$25.12.
- Biopharma end market led growth; academic/government and diagnostics were soft.
- Completed Clario acquisition ($9B) and highlighted NVIDIA and OpenAI collaborations.
Revenue$11.005B-10% QoQ
EPS$5.44-17% QoQ
Gross margin40.67%Reported
Operating margin16.93%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
M&A
Clario acquisition completed, contributing to guidance.
Demand
Clinical research business delivering strong growth and share gains.
Show 3 more callouts
AI
AI collaboration with NVIDIA progressing toward commercialization.
Margins
Tariffs and related FX impact Q1 margins by 80 bps.
Macro
Higher inflation placeholder in guidance for future quarters.
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $11.005B | -10% QoQ |
| EPS | $5.44 | -17% QoQ |
| Gross margin | 40.67% | Reported |
| Operating margin | 16.93% | Reported |
| Free cash flow | $0.816B | Reported |
| Capex | $0.376B | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| Capex | FY2026 | $1.9B–$2.1B | $2B | Guided |
| EPS | FY2026 | $24.64–$25.12 | $24.88 | Raised |
| EPS | FY2026 Q2 | $5.69–$5.74 | $5.71 | Guided |
| Free cash flow | FY2026 | $6.9B–$7.4B | $7.15B | Guided |
| Revenue | FY2026 | $47.3B–$48.1B | $47.7B | Raised |
AI, capex & demand read
Management read
Confident
Management expressed confidence in meeting guidance and highlighted strong execution, innovation, and strategic acquisitions as drivers of future growth.
Management AI read
Management discussed AI adoption as a positive tailwind, citing collaborations with NVIDIA and OpenAI, and believes AI will accelerate scientific discovery and enhance their competitive advantage. They are embedding AI across instruments and clinical research to improve customer outcomes.
all 2 named companies below
Companiesreturns since call
Partners
Partners
Mark Casper
Thermo Fisher is integrating NVIDIA's AI into lab instruments to create commercial workflow solutions, potentially boosting NVIDIA's presence in life sciences.
Evidence
“We announced a strategic collaboration with NVIDIA, combining our leadership and laboratory technologies with Navidius advanced AI capabilities.”
OPENAI
Partners
Mark Casper
Thermo Fisher's earlier collaboration with OpenAI is supporting clinical research AI tools, though no new specifics were provided.
Evidence
“we had announced some time ago with open Ai and you know customers value that and that position is very well”
Methodology & coverage
Management-only analysis. All 2 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.